Thieblemont C, Pack S, Sakai A, Beaty M, Pak E, Vortmeyer A O, Wellmann A, Zhuang Z, Jaffe E S, Raffeld M
Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Leukemia. 1999 Jan;13(1):85-91. doi: 10.1038/sj.leu.2401216.
Deletions and rearrangements involving the long arm of chromosome 11 are not infrequent occurrences in the non-Hodgkin's lymphomas. Recently, a tumor suppressor gene, the multiple endocrine neoplasia type 1 gene (MEN1) was cloned and mapped to chromosome 11q13. To assess the potential involvement of this gene in lymphomagenesis, we examined 94 primary cases of lymphoma and 12 cell lines by a combination of fluorescent in situ hybridization and PCR-SSCP analysis. In our initial analysis of 41 primary B or T lymphomas, MEN1 FISH analysis revealed allelic deletions in 15 cases (three of four B cell chronic lymphocytic leukemias, six of 15 follicular lymphomas, three of nine diffuse large B cell lymphomas, two of five mantle cell lymphomas, one of four Burkitt's lymphoma). To discern whether the MEN1 gene was in fact the target of the deletions, we assessed 20 of these 41 cases and an additional 74 primary lymphomas and 12 cell lines for MEN1 gene mutations using PCR-SSCP analysis. Abnormal SSCP patterns were found in exon 2 in two of the primary lymphoma cases and in one of the cell lines, but not in any of the original cases that showed MEN1 deletions by FISH. Furthermore, sequencing analysis revealed that the abnormal SSCP patterns in exon 2 were the result of a previously described genetic polymorphism (S145S: AGC --> ACT), and in one sample, the result of this S145S polymorphism associated with a second nucleotide substitution at position 498 which left the encoded amino acid unchanged. Our study indicates that the 11q13 locus is a frequent target of deletion in lymphoid neoplasms, but that there are no associated mutations of the MEN1 gene. This suggests that the 11q deletions either target another gene in lymphomas, or that the MEN1 gene is inactivated through means other than mutation.
11号染色体长臂的缺失和重排在非霍奇金淋巴瘤中并非罕见。最近,一个肿瘤抑制基因,即多发性内分泌肿瘤1型基因(MEN1)被克隆并定位于11号染色体q13区。为了评估该基因在淋巴瘤发生中的潜在作用,我们通过荧光原位杂交和PCR-SSCP分析相结合的方法,检测了94例原发性淋巴瘤病例和12个细胞系。在我们对41例原发性B或T淋巴瘤的初步分析中,MEN1荧光原位杂交分析显示15例存在等位基因缺失(4例B细胞慢性淋巴细胞白血病中的3例、15例滤泡性淋巴瘤中的6例、9例弥漫性大B细胞淋巴瘤中的3例、5例套细胞淋巴瘤中的2例、4例伯基特淋巴瘤中的1例)。为了确定MEN1基因是否实际上是缺失的靶点,我们使用PCR-SSCP分析对这41例中的20例以及另外74例原发性淋巴瘤和12个细胞系进行了MEN1基因突变评估。在2例原发性淋巴瘤病例和1个细胞系的外显子2中发现了异常的SSCP模式,但在任何通过荧光原位杂交显示MEN1缺失的原始病例中均未发现。此外,测序分析表明外显子2中的异常SSCP模式是先前描述的基因多态性(S145S:AGC→ACT)的结果,在一个样本中,这种S145S多态性与第498位的第二个核苷酸替换相关,该替换使编码的氨基酸不变。我们的研究表明,11q13位点是淋巴肿瘤中常见的缺失靶点,但不存在与MEN1基因相关的突变。这表明11q缺失要么靶向淋巴瘤中的另一个基因,要么MEN1基因是通过突变以外的方式失活的。